The real story isn't the funding round—it's that personalized medicine 3D printing is finally leaving the hype phase. CurifyLabs's $14M validates what bioprinting evangelists have been promising for a decade: on-demand drug manufacturing at point-of-care actually works at scale now, not just in labs. Meanwhile, firmware updates keep quietly compounding: Marlin 2.1.2.8 and PrusaSlicer 2.9.6 are the unglamorous backbone making consumer hardware reliable enough for this shift. Skip the silk PLA bundle noise and the gun-control policy theater—watch the actual engineering advances in space fabrication (Joule heating for vacuum environments) and microscale precision (two-photon polymerization bellows), because those breakthroughs unlock industrial adoption faster than any headline.